The United States Patent and Trademark Office (USPTO) has issued a patent (number 8,821,930) covering Supernus Pharmaceuticals' novel once-daily extended-release oxcarbazepine product, Oxtellar XR. The patent was issued on September 2, 2014 and provides protection for the product with expiration that is no earlier than April 13, 2027.
"With this issuance, Oxtellar XR is protected through four issued US patents," said Jack A. Khattar, president and chief executive officer, of Supernus. "As we continue to grow the market for our once daily products, expanding our intellectual property franchise is of the utmost importance to ensure the sustainability and competitive advantage of our product portfolio."
Supernus has several additional patent applications for extended-release oxcarbazepine and extended-release topiramate pending in other geographic regions.